[
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know",
    "summary": "LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.",
    "url": "https://finnhub.io/api/news?id=88735d0fcb63a6cfb4e581b50d0e4d2668db1e9868c3c8c6eee0408602cc25e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759773420,
      "headline": "Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know",
      "id": 136989547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.",
      "url": "https://finnhub.io/api/news?id=88735d0fcb63a6cfb4e581b50d0e4d2668db1e9868c3c8c6eee0408602cc25e5"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down as Pfizer Compromise Optimism Fades -- Health Care Roundup",
    "summary": "Health Care Down as Pfizer Compromise Optimism Fades -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=7dc72b5a2308230d585a3fb9d7d102635ec60ece7757951eaf36ced419b65e0f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759772460,
      "headline": "Health Care Down as Pfizer Compromise Optimism Fades -- Health Care Roundup",
      "id": 137110314,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Health Care Down as Pfizer Compromise Optimism Fades -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=7dc72b5a2308230d585a3fb9d7d102635ec60ece7757951eaf36ced419b65e0f"
    }
  },
  {
    "ts": null,
    "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=4a2f2d1ee6af80f171ccf5b5b8f8e30100be21282ca4976723d9a30aec68327b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759767001,
      "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
      "id": 136989548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=4a2f2d1ee6af80f171ccf5b5b8f8e30100be21282ca4976723d9a30aec68327b"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.",
    "summary": "The  SPDR S&P Biotech  exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago.  The biotech run-up over the past week or so has been fueled by the same drug-pricing deal between  Pfizer  and President Donald Trump that set off a surge in Big Pharma share prices last Tuesday, along with a spate of acquisitions.  “Investors are naturally jittery, since prior rallies haven’t been sustained,” Cantor Fitzgerald analysts Josh Schimmer and Eric Schmidt wrote in a note on Friday.",
    "url": "https://finnhub.io/api/news?id=1a95ce3436e3b1e0658a591dd6e2f3d6e5e99a3906db105e7c009d2923a86cfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759764780,
      "headline": "Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.",
      "id": 136989354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The  SPDR S&P Biotech  exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago.  The biotech run-up over the past week or so has been fueled by the same drug-pricing deal between  Pfizer  and President Donald Trump that set off a surge in Big Pharma share prices last Tuesday, along with a spate of acquisitions.  “Investors are naturally jittery, since prior rallies haven’t been sustained,” Cantor Fitzgerald analysts Josh Schimmer and Eric Schmidt wrote in a note on Friday.",
      "url": "https://finnhub.io/api/news?id=1a95ce3436e3b1e0658a591dd6e2f3d6e5e99a3906db105e7c009d2923a86cfc"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?",
    "summary": "ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.",
    "url": "https://finnhub.io/api/news?id=5fcaf3a41fe0cdbdb83a5783564f188f7555554b2bd1b20dff5217998e180b68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759759860,
      "headline": "AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?",
      "id": 136989145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.",
      "url": "https://finnhub.io/api/news?id=5fcaf3a41fe0cdbdb83a5783564f188f7555554b2bd1b20dff5217998e180b68"
    }
  },
  {
    "ts": null,
    "headline": "Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth",
    "summary": "Marketing agency Luckie announced today that Scott Gelber is the company's new Chief Executive Officer, marking a key leadership transition as the firm looks to accelerate growth across the Southeast.",
    "url": "https://finnhub.io/api/news?id=2ec4a07aa0a4059b8735838f9aee6454a296b27354243163a40a560f2716e784",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759758960,
      "headline": "Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth",
      "id": 136989551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Marketing agency Luckie announced today that Scott Gelber is the company's new Chief Executive Officer, marking a key leadership transition as the firm looks to accelerate growth across the Southeast.",
      "url": "https://finnhub.io/api/news?id=2ec4a07aa0a4059b8735838f9aee6454a296b27354243163a40a560f2716e784"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
    "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
    "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755780,
      "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
      "id": 136989147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
      "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c"
    }
  },
  {
    "ts": null,
    "headline": "Trump says the US has secured $17 trillion in new investments. The real number is likely much less",
    "summary": "The White House website lists total investments at $8.8 trillion, though that figure appears to be padded with some investment commitments made during Joe Biden's presidency.  The White House didn't lay out the math after multiple requests as to how Trump calculated $17 trillion in investment commitments.",
    "url": "https://finnhub.io/api/news?id=aefe76814e2eb40dca9a5ce8693aa6e4a69c1e923806a5964d1240bdfcd9f01a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755632,
      "headline": "Trump says the US has secured $17 trillion in new investments. The real number is likely much less",
      "id": 136989389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The White House website lists total investments at $8.8 trillion, though that figure appears to be padded with some investment commitments made during Joe Biden's presidency.  The White House didn't lay out the math after multiple requests as to how Trump calculated $17 trillion in investment commitments.",
      "url": "https://finnhub.io/api/news?id=aefe76814e2eb40dca9a5ce8693aa6e4a69c1e923806a5964d1240bdfcd9f01a"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=8ec2dd4d13a947bd870e0f4cb958c9f94627453030d3abec013fc908291f87cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755603,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 136989554,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=8ec2dd4d13a947bd870e0f4cb958c9f94627453030d3abec013fc908291f87cf"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE): Exploring Valuation Opportunity After Recent 15% Share Price Uptick",
    "summary": "Pfizer (PFE) has seen its stock price move gradually higher over the past week, rising nearly 15% in that period. Investors seem interested in the company’s recent performance and underlying fundamentals, given these moderate gains. See our latest analysis for Pfizer. Pfizer's latest rally adds to a period of modest but steady momentum, building on its 1-year total shareholder return of just 0.3%. While the company’s share price has edged up recently, the bigger story is how sentiment could...",
    "url": "https://finnhub.io/api/news?id=2b014e1bce9ff46693dad0bb835ba92e6ff4e857f65443582a73183ede508b17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759750031,
      "headline": "Pfizer (PFE): Exploring Valuation Opportunity After Recent 15% Share Price Uptick",
      "id": 136989555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has seen its stock price move gradually higher over the past week, rising nearly 15% in that period. Investors seem interested in the company’s recent performance and underlying fundamentals, given these moderate gains. See our latest analysis for Pfizer. Pfizer's latest rally adds to a period of modest but steady momentum, building on its 1-year total shareholder return of just 0.3%. While the company’s share price has edged up recently, the bigger story is how sentiment could...",
      "url": "https://finnhub.io/api/news?id=2b014e1bce9ff46693dad0bb835ba92e6ff4e857f65443582a73183ede508b17"
    }
  },
  {
    "ts": null,
    "headline": "4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio",
    "summary": "Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.",
    "url": "https://finnhub.io/api/news?id=533859fbdfcb096ceb9df1e2dd77bba2acefc64f2c9661a71eeaf2096f87b401",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759748220,
      "headline": "4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio",
      "id": 136989556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.",
      "url": "https://finnhub.io/api/news?id=533859fbdfcb096ceb9df1e2dd77bba2acefc64f2c9661a71eeaf2096f87b401"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Buy Pfizer Stock Now",
    "summary": "After years of underperformance, the future is looking brighter for the drugmaker.",
    "url": "https://finnhub.io/api/news?id=577f1f14e6300d028e03ec62b2023205e3c3ab5b12d6bdf00c939689b9f32d9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759741140,
      "headline": "3 Reasons to Buy Pfizer Stock Now",
      "id": 136989557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After years of underperformance, the future is looking brighter for the drugmaker.",
      "url": "https://finnhub.io/api/news?id=577f1f14e6300d028e03ec62b2023205e3c3ab5b12d6bdf00c939689b9f32d9a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts",
    "summary": "Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=24d4b61b23a79e8b055fa8fc49d669d2e6b5787aef323f990dc0110823bd36c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759737600,
      "headline": "Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts",
      "id": 136987032,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399981576/image_1399981576.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=24d4b61b23a79e8b055fa8fc49d669d2e6b5787aef323f990dc0110823bd36c0"
    }
  },
  {
    "ts": null,
    "headline": "Trump administration could lower drug prices by making other nations pay more",
    "summary": "The Trump administration often touts its efforts to lower prices in the U.S. by matching what other countries pay, but there’s more to this policy story.",
    "url": "https://finnhub.io/api/news?id=e776a8e1d1dadee006b211d6226451ab57f8b477fea8f6fc6e68439a332242e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759735924,
      "headline": "Trump administration could lower drug prices by making other nations pay more",
      "id": 136989558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Trump administration often touts its efforts to lower prices in the U.S. by matching what other countries pay, but there’s more to this policy story.",
      "url": "https://finnhub.io/api/news?id=e776a8e1d1dadee006b211d6226451ab57f8b477fea8f6fc6e68439a332242e7"
    }
  }
]